

Citations and Reference Literature: Ginkgo

Citations

1. Blumenthal M, Busse W, Goldberg A et al. Ginkgo biloba leaf extract. The Complete German Commission E Monographs. Austin , Texas: American Botanical Council: Integrative Medicine Communications; 1998:136-138.
2. WHO. Folium Ginkgo. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:154-167.
3. ESCOP. Ginkgo Folium. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003.
4. Upton R. Ginkgo leaf, Ginkgo leaf dry extract. American Herbal Pharmacopoeia. Scotts Valley, Calif; 2003.
5. DeFeudis FV. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Wiesbaden: Ullstein Medical; 1998.
6. Van Beek TA. Ginkgo biloba. London: Taylor and Francis; 2000.
7. Stockley I. Stockley's Drug Interactions. 6th ed. London: Pharmaceutical Press; 2002.
8. Treasure JE. MEDLINE and the mainstream manufacture of misinformation. J Am Herbalists Guild 2006;6:50-56.
9. Galluzzi S, Zanetti O, Binetti G et al. Coma in a patient with Alzheimer's disease taking low dose trazodone and Ginkgo biloba. J Neurol Neurosurg Psychiatry 2000;68:679-680.
10. Kaye AD, Clarke RC, Sabar R et al. Herbal medicines: current trends in anesthesiology practice—a hospital survey. J Clin Anesth 2000;12:468-471.
11. Tsen LC, Segal S, Pothier M, Bader AM. Alternative medicine use in presurgical patients. Anesthesiology 2000;93:148-151.
12. Fessenden JM, Wittenborn W, Clarke L. Ginkgo biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001;67:33-35.
13. Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Ginkgo biloba use after liver transplantation. Transpl Int 2002;15:377-379.
14. Juretzek W, Muller WE. [Overview of phytopharmaceuticals for therapy of dementia: quality and activity of Ginkgo biloba extract]. Pharm Unserer Zeit 2002;31:370-375.
15. Naidu MU, Kumar KV, Mohan IK et al. Protective effect of Ginkgo biloba extract against doxorubicin-induced cardiotoxicity in mice. Indian J Exp Biol 2002;40:894-900.
16. Fong KC, Kinnear PE. Retrobulbar haemorrhage associated with chronic Ginkgo biloba ingestion. Postgrad Med J 2003;79:531-532.
17. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108.
18. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-1776.
19. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter]. Lancet 1998;352.
20. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-595.
21. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000;34:1478-1482.
22. Kohler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004;15:303-309.
23. Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003;25:251-253.
24. Jiang X, Williams KM, Liauw WS et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-432.
25. Ha SW, Yi CJ, Cho CK et al. Enhancement of radiation effect by Ginkgo biloba extract in C3H mouse fibrosarcoma. Radiother Oncol 1996;41:163-167.
26. Sagar S, Wong R. Chinese medicine and supportive cancer care; a model for an evidence-based integrative approach. Evid -Based Integr Med 2003;1:11-26.
27. Biber A, Koch E. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 1999;65:192-193.
28. Fourtillan JB, Brisson AM, Girault J et al. [Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. Therapie 1995;50:137-144.
29. Kressmann S, Biber A, Wonnemann M et al. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 2002;54:1507-1514.
30. Li CL, Wong YY. The bioavailability of ginkgolides in Ginkgo biloba extracts. Planta Med 1997;63:563-565.
31. Brochet D, Chermat R, DeFeudis FV, Drieu K. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 1999;33:249-256.

Citations and Reference Literature: Ginkgo

32. Wada K, Sasaki K, Miura K et al. Isolation of bilobalide and ginkgolide A from *Ginkgo biloba* L. shorten the sleeping time induced in mice by anesthetics. *Biol Pharm Bull* 1993;16:210-212.
33. Itil T, Martorano D. Natural substances in psychiatry (*Ginkgo biloba* in dementia). *Psychopharmacol Bull* 1995;31:147-158.
34. Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. *J Pharm Pharmacol* 2005;57:751-758.
35. Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, *Panax ginseng* and *Ginkgo biloba*. *Drugs Aging* 2005;22:525-539.
36. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clin Pharmacol Ther* 2002;72:276-287.
37. Duche JC, Barre J, Guinot P et al. Effect of *Ginkgo biloba* extract on microsomal enzyme induction. *Int J Clin Pharmacol Res* 1989;9:165-168.
38. Markowitz JS, Donovan JL, Lindsay DeVane C et al. Multiple-dose administration of *Ginkgo biloba* did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. *J Clin Psychopharmacol* 2003;23:576-581.
39. Yasui-Furukori N, Furukori H, Kaneda A et al. The effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil. *J Clin Pharmacol* 2004;44:538-542.
40. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. *Ginkgo biloba*: evaluation of CYP2C9 drug interactions in vitro and in vivo. *Am J Ther* 2006;13:24-31.
41. Greenblatt DJ, von Moltke LL, Luo Y et al. *Ginkgo biloba* does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. *J Clin Pharmacol* 2006;46:214-221.
42. Yin OQ, Tomlinson B, Waye MM et al. Pharmacogenetics and herb-drug interactions: experience with *Ginkgo biloba* and omeprazole. *Pharmacogenetics* 2004;14:841-850.
43. Chang TK, Chen J, Yeung EY. Effect of *Ginkgo biloba* extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. *Toxicol Appl Pharmacol* 2006;213:18-26.
44. Chang TK, Chen J, Teng XW. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by *Ginkgo biloba* in cultured hepatocytes. *Drug Metab Dispos* 2005;34:234-242.
45. Yale SH, Glurich I. Analysis of the inhibitory potential of *Ginkgo biloba*, *Echinacea purpurea*, and *Serenoa repens* on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. *J Altern Complement Med* 2005;11:433-439.
46. Sugiyama T, Kubota Y, Shinozuka K et al. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with *Ginkgo biloba* extract. *Food Chem Toxicol* 2004;42:953-957.
47. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the *Ginkgo biloba* extract. *Biochem Biophys Res Commun* 2004;318:1072-1078.
48. Mauro VF, Mauro LS, Kleshinski JF et al. Impact of *Ginkgo biloba* on the pharmacokinetics of digoxin. *Am J Ther* 2003;10:247-251.
49. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. *Toxicol In Vitro* 2005;20:187-210.
50. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. *Life Sci* 2006;78:2116-2130.
51. DeFeudis FV, Drieu K. *Ginkgo biloba* extract (EGb 761) and CNS functions: basic studies and clinical applications. *Curr Drug Targets* 2000;1:25-58.
52. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of *Ginkgo biloba* extracts. *Phytomedicine* 2005;12:10-16.
53. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of *Ginkgo biloba* on fluidity of blood and peripheral microcirculation in volunteers. *Arzneimittelforschung* 1990;40:589-593.
54. Belougne E, Aguejoui O, Imbault P et al. Experimental thrombosis model induced by laser beam: application of aspirin and an extract of *Ginkgo biloba*, EGb 761. *Thromb Res* 1996;82:453-458.
55. Kim YS, Pyo MK, Park KM et al. Antiplatelet and antithrombotic effects of a combination of ticlopidine and *Ginkgo biloba* ext (EGb 761). *Thromb Res* 1998;91:33-38.
56. Meisel C, John A, Roots I. Fatal intracerebral mass bleeding associated with *Ginkgo biloba* and ibuprofen. *Atherosclerosis* 2003;167:367.
57. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. *Stroke* 1994;25:2331-2336.
58. Helgason CM, Tortorice KL, Winkler SR et al. Aspirin response and failure in cerebral infarction. *Stroke* 1993;24:345-350.
59. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. *Can J Cardiol* 1995;11:221-227.

Citations and Reference Literature: Ginkgo

60. Smith PF, MacLennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). *J Ethnopharmacol* 1996;50:131-139.
61. Smith NM, Pathansali R, Bath PM. Altered megakaryocyte-platelet-haemostatic axis in patients with acute stroke. *Platelets* 2002;13:113-120.
62. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. *BMJ* 2002;325:762-765.
63. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. *BMJ* 2002;325:828-831.
64. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *BMJ* 2004;329:15-19.
65. Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS. Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. *Pharmacol Res* 2004;49:133-142.
66. Chao JC, Hung HC, Chen SH, Fang CL. Effects of Ginkgo biloba extract on cytoprotective factors in rats with duodenal ulcer. *World J Gastroenterol* 2004;10:560-566.
67. Fukaya H, Kanno H. [Experimental studies of the protective effect of Ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats]. *Nippon Jibiinkoka Gakkai Kaiho* 1999;102:907-917.
68. Ozturk G, Anlar O, Erdogan E et al. The effect of Ginkgo extract EGb761 in cisplatin-induced peripheral neuropathy in mice. *Toxicol Appl Pharmacol* 2004;196:169-175.
69. Bagnis C, Deray G, Dubois M et al. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. *Nephrol Dial Transplant* 1996;11:507-513.
70. Becker K, Braquet P, Forster W. Influence of the specific antagonist of PAF-acether, BN 52021, and of Ginkgo extract on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB₂. *Biomed Biochim Acta* 1988;47:S165-168.
71. Foegh ML, Khirabadi BS, Rowles JR et al. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. *Transplantation* 1986;42:86-88.
72. Varga E, Bodi A, Ferdinandy P et al. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. *J Cardiovasc Pharmacol* 1999;34:711-717.
73. Mahmoud F, Abul H, Onadeko B et al. In vitro effects of Ginkgolide B on lymphocyte activation in atopic asthma: comparison with cyclosporin A. *Jpn J Pharmacol* 2000;83:241-245.
74. Barth SA, Inselmann G, Engemann R, Heidemann HT. Influences of Ginkgo biloba on cyclosporin A-induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. *Biochem Pharmacol* 1991;41:1521-1526.
75. Grino JM. BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure—a double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation. *Ann Intern Med* 1994;121:345-347.
76. Tilgner S. The contented kidney. *Herbal Transitions* 1998;3:2-9.
77. Butterly DW, Spurney RF, Ruiz P et al. Role of platelet activating factor in kidney transplant rejection in the rat. *Kidney Int* 1995;48:337-343.
78. Agha AM, El-Fattah AA, Al-Zuhair HH, Al-Rikabi AC. Chemopreventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: amelioration of doxorubicin cardiotoxicity. *J Exp Clin Cancer Res* 2001;20:39-50.
79. Erdogan H, Fadilliofölu E, Kotuk M et al. Effects of Ginkgo biloba on plasma oxidant injury induced by bleomycin in rats. *Toxicol Ind Health* 2006;22:47-52.
80. Iraz M, Erdogan H, Kotuk M et al. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. *Pharmacol Res* 2006.
81. Celik I, Cihangiroglu M, Ilhan N et al. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. *Basic Clin Pharmacol Toxicol* 2005;97:325-332.
82. Sener G K, Omurtag G Z, Sehirli O et al. Protective effects of Ginkgo biloba against acetaminophen-induced toxicity in mice. *Mol Cell Biochem* 2006;283:39-45.
83. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006; 17:1586-1591.
84. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 1997;15:1318-1332.
85. Hauns B, Haring B, Kohler S et al. Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. *Phytother Res* 2001;15:34-38.
86. Hauns B, Haring B, Kohler S et al. Phase II study with 5-fluorouracil and Ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer. *Arzneimittelforschung* 1999;49:1030-1034.
87. DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. *Fundam Clin Pharmacol* 2003;17:405-417.

Citations and Reference Literature: Ginkgo

88. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. *Hum Psychopharmacol* 2002;17:279-284.
89. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. *J Sex Marital Ther* 1998;24:139-143.
90. Balon R. Ginkgo biloba for antidepressant-induced sexual dysfunction? *J Sex Marital Ther* 1999;25:1-2.
91. Levine SB. Caution recommended. *J Sex Marital Ther* 1999;25:2-5.
92. Ashton AK, Ahrens K, Gupta S, Masand PS. Antidepressant-induced sexual dysfunction and Ginkgo biloba. *Am J Psychiatry* 2000;157:836-837.
93. Ellison JM, DeLuca P. Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. *J Clin Psychiatry* 1998;59:199-200.
94. Schubert H, Halama P. Primary therapy-resistant depressive instability in elderly patients with cerebral disorders: efficacy of a combination of Ginkgo biloba extract EGb 761 with antidepressants. *Geriatr Forsch* 1993;1:45-53.
95. Naidu MU, Shifow AA, Kumar KV, Ratnakar KS. Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats. *Phytomedicine* 2000;7:191-197.
96. Jung HW, Chang SO, Kim CS et al. Effects of Ginkgo biloba extract on the cochlear damage induced by local gentamicin installation in guinea pigs. *J Korean Med Sci* 1998;13:525-528.
97. Miman MC, Ozturan O, Iraz M et al. Amikacin ototoxicity enhanced by Ginkgo biloba extract (EGb 761). *Hear Res* 2002;169:121-129.
98. Zhang XY, Zhou DF, Zhang PY et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. *J Clin Psychiatry* 2001;62:878-883.
99. Zhou D, Zhang X, Su J et al. The effects of classic antipsychotic haloperidol plus the extract of Ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. *Chin Med J (Engl)* 1999;112:1093-1096.
100. Zhang XY, Zhou DF, Su JM, Zhang PY. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. *J Clin Psychopharmacol* 2001;21:85-88.
101. Breggin PR. *Brain Disabling Treatments in Psychiatry*. New York: Springer; 1997.
102. Norred CL, Zamudio S, Palmer SK. Use of complementary and alternative medicines by surgical patients. *AANA J* 2000;68:13-18.
103. Norred CL, Finlayson CA. Hemorrhage after the preoperative use of complementary and alternative medicines. *AANA J* 2000;68:217-220.
104. Bebbington A, Kulkarni R, Roberts P. Ginkgo biloba: persistent bleeding after total hip arthroplasty caused by herbal self-medication. *J Arthroplasty* 2005;20:125-126.
105. Destro MW, Speranzini MB, Cavalheiro Filho C et al. Bilateral haematoma after rhytidoplasty and blepharoplasty following chronic use of Ginkgo biloba. *Br J Plast Surg* 2005;58:100-101.
106. Yagmur E, Piatkowski A, Groger A et al. Bleeding complication under Ginkgo biloba medication. *Am J Hematol* 2005;79:343-344.
107. Norred CL, Brinker F. Potential coagulation effects of preoperative complementary and alternative medicines. *Altern Ther Health Med* 2001;7:58-67.
108. Oliver C, Guilleme V, Héry F et al. Effect of Ginkgo biloba extract on the hypothalamic-pituitary-adrenal axis and plasma catecholamine levels in stress. *Eur J Endocrinol* 1993;130 Suppl 2:207 (P203.072).
109. Chatterjee SS, Kondratskaya EL, Krishtal OA. Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators. *Pharmacopsychiatry* 2003;36 Suppl 1:S68-77.
110. Davies JA, Johns L, Jones FA. Effects of bilobalide on cerebral amino acid neurotransmission. *Pharmacopsychiatry* 2003;36 Suppl 1:S84-88.
111. Gatch MB, Jung ME, Wallis CJ, Lal H. Effects of GABA(A) compounds on mCPP drug discrimination in rats. *Life Sci* 2002;71:2657-2665.
112. Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized, double-blind, placebo-controlled cross over trial]. *Ugeskr Laeger* 2003;165:1868-1871.
113. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. *Neurology* 1998;50:1933-1934.
114. Loebstein R, Yonath H, Peleg D et al. Interindividual variability in sensitivity to warfarin: nature or nurture? *Clin Pharmacol Ther* 2001;70:159-164.
115. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994;121:676-683.
116. Dergal JM, Gold JL, Laxer DA et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. *Drugs Aging* 2002;19:879-886.
117. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* 1998;158:2200-2211.
118. Harkness R, Bratman S. *Mosby's Handbook of Drug-Herb and Drug-Supplement Interactions*. St Louis: Mosby; 2003.

Citations and Reference Literature: Ginkgo

119. Wada K, Ishigaki S, Ueda K et al. An antivitamin B6, 4'-methoxypyridoxine, from the seed of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 1985;33:3555-3557.
120. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005;29:755-758.
121. Fowler JS, Wang GJ, Volkow ND et al. Evidence that Ginkgo biloba extract does not inhibit MAO A and B in living human brain. Life Sci 2000;66:PL141-146.
122. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600-611.
123. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res 2002;108:151-160.
124. Sugiyama T, Kubota Y, Shinozuka K et al. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450-mediated mechanism in aged rats. Life Sci 2004;75:1113-1122.
125. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997;17:342-356.